Entering text into the input field will update the search result below

Novo files two U.S. applications for oral semaglutide

Mar. 20, 2019 11:07 AM ETNovo Nordisk A/S (NVO) StockBy: Douglas W. House, SA News Editor2 Comments
  • Novo Nordisk (NVO -0.1%) has submitted two marketing applications to the FDA related to oral semaglutide, a once-daily glucagon-like peptide-1 (GLP-1) receptor agonist in pill form.
  • The first application seeks approval as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes (T2D). It was made with a Priority Viewer Voucher which shortens the review clock to six months.
  • The second application seeks a cardiovascular (CV) benefit claim, specifically, to reduce the risk of major adverse CV events (MACE) in adults with T2D with established CV disease. The company expects the standard 10-month review period for this filing.
  • It has also submitted a supplemental marketing application for once-weekly Ozempic (semaglutide) injection (0.5 mg or 1.0 mg) seeking a CV benefit claim.

Recommended For You

About NVO Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
NVO--
Novo Nordisk A/S
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.